Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
August 5, 2026
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
May 28, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
May 6, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
May 5, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
May 4, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
April 28, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
March 10, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
March 9, 2026